The Best Covid-19 Stock for the Second Wave

As a new breed of retail investors have arrived on the stock market, penny stock trading has seen an incredible resurgence, especially in the months between March and June, 2020. Now with a Second Wave hitting Europe, South America, India and likely North America as well, stock market volatility is likely to make another good case for penny stocks in the November to March period ahead.

Covid-19 stocks are a special breed unto themselves if you have been following them. Witness today's case (I have no affiliation with this company though I do hold a modest amount of the stock):

$HALB claims it has a preventative nasal spray that I have found rather promising. You can read the patent details here. The provisional patent, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” was filed recently with the U.S. Patent and Trademark Office by its inventor, Mitchell S. Felder, MD.

Now there’s new research to back it up. Halberd Corporation (OTC PINK:HALB) reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. 

Today in the morning the $HALB stock is up around 200% on the news. Also in October their leadership team has gotten stronger.

When a company holds the exclusive rights to the COVID-19 extracorporeal treatment technology and in the era of sentiment plays in Covid-19, it’s likely a company that could show massive stock gains. Remember here we are talking about a stock worth under 2 cents.

The current price rests at $0.017.

The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike Protein. The performance has exceeded expectations, and Halberd and ASU intend to file for joint patent protection.

Development continues toward three major potential utilizations of the antibody against the Coronavirus:

1. A Preventative;
2. A Diagnostic, and
3. A Therapeutic Treatment.

Even if this news is a bit too good to be true, the stock should go up to at least 0.08 in my opinion in October, 2020. This is based on Covid-19 stocks in general when they have positive news. Given the advent of the second wave, we are likely to see Covid-19 stocks with an off-chance of having real world benefits do pretty well. I do not follow the research very closely, but I was already invested in the stock given it’s potential to race up.

This is new territory for the stock and has never previously gone over 2 cents. Thus it could race up if consensus is arrived that it’s a legit option for Covid-19 treatments. Ideally you want to be in a stock before a 200% one-day gain. But if you weren’t, it’s still a decent bet for the week of October 12th, 2020.

Do note that penny stocks are extremely risky, volatile and even more so if it's a Pink-slip OTC stock. However, Covid-19 treatments will be very much in demand in 2021 and likely 2022 as well.